222P - FOLFIRINOX for advanced pancreato-biliary adenocarcinoma, a multi-centre retrospective analysis: The South Australian Experience

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Anti-Cancer Agents & Biologic Therapy
Hepatobiliary Cancers
Pancreatic Cancer
Presenter Myron Klevansky
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors M. Klevansky1, A.R.A. Mislang2, V. Kwatra3, C.L. Griffiths4, A.H. Hsieh2, H. Takhar3, S. Ullah5, C.S. Karapetis2, G. Kichenadasse2, T.J. Price6, T. Healey4, N. Singhal3, A. Roy2
  • 1Medical Oncology, Flinders Centre for Innovation in Cancer-FCIC, 5042 - Bedford Park/AU
  • 2Medical Oncology, Flinders Centre for Innovation in Cancer-FCIC, Bedford Park/AU
  • 3Medical Oncology, Royal Adelaide Hospital RAH Cancer Centre, Adelaide/AU
  • 4Medical Oncology, Calvary North Adelaide Hospital-North Adelaide Oncology, Adelaide/AU
  • 5Flinders Centre For Epidemiology And Biostatistics, Flinders University, Bedford Park/AU
  • 6Medical Oncology, Queen Elizabeth Hospital, Woodville/AU

Abstract

Aim/Background

FOLFIRINOX chemotherapy regimen has been shown to improve overall survival (OS) and progression free survival (PFS) in patients with metastatic pancreatic cancer, however, with an associated increase in toxicity. The primary aim of this multi-centre retrospective analysis was to evaluate toxicity and adverse events and the secondary objective was to assess the efficacy of this regimen in an Australian setting.

Methods

A retrospective analysis of patients treated with FOLFIRINOX was conducted at four South Australian tertiary referral hospitals between April 2013 and April 2014. Toxicity was graded as per CTCAE version 4.0. Overall survival and tumour response were analysed.

Results

A total of 30 patients were identified. 63.3% of patients had metastatic disease. The median age was 57 (range 53–63) and the median number of cycles delivered was 5 (range 1-12). ECOG performance status was 1 or 2. 13% patients completed full 12 cycles of FOLFIRINOX. 36.7% of patients received FOLFIRINOX as neoadjuvant treatment with a resection rate of 27%. G3/4 neutropenia occurred in 23.3% patients with febrile neutropenia occurring in 13.3%, diarrhea in 10% and peripheral neuropathy in 10% of patients. The mOS for patients with locally advanced pancreatic cancer was 23.9 months and 12.3 months for patients with metastatic disease with a 1 year SR of 52% in this group.

Conclusions

This multi-centre audit from four tertiary South Australian Hospitals reveal that FOLFIRINOX can be safely delivered in appropriate patient groups outside trial cohort. The toxicity profile and outcome is comparable to other studies using FOLFIRINOX in both LAPC and metastatic disease.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.